Recommendation ID
NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and overall survival.
Any explanatory notes
(if applicable)
The use of enzalutamide for treating metastatic hormone-relapsed prostate cancer previously treated with abiraterone is not covered by this guidance.

Source guidance details

Comes from guidance
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Date issued
July 2014

Other details

Is this a recommendation for the use of a technology only in the context of research? N/A  
Is it a recommendation that suggests collection of data or the establishment of a register?   N/A  
Last Reviewed 07/10/2014